Revolution Medicines to present updated Phase 1 data for zoldonrasib

Revolution Medicines (RVMD) announced updated Phase 1 clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer, NSCLC. Results were highlighted in the official press program at the American Association for Cancer Research, AACR. Zoldonrasib was generally well tolerated and demonstrated a safety profile consistent with previously reported findings. Treatment-related adverse events of any grade occurring in at least 15% of patients were nausea, vomiting, diarrhea, and rash. The majority of TRAEs were Grade 1 in severity. Grade 3 TRAEs occurred in 13% of patients and resolved following dose interruption; TRAEs led to treatment discontinuation in 5% of patients. No Grade 4 or Grade 5 TRAEs were observed. Zoldonrasib demonstrated a favorable mean dose intensity of 94%.